Pacira Pharma (PCRX) Misses Q2 EPS by 35c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira Pharma (PCRX) Misses Q2 EPS by 35c

Pacira BioSciences Reports Second Quarter 2022 Financial Results

August 3, 2022 8:01 AM EDT

-- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition
-- Strong topline performance delivers solid net income and significantly positive adjusted EBITDA--
-- Conference call today at 8:30 a.m. ET --

TAMPA, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the second quarter of 2022.

Second Quarter 2022 Financial Highlights

... More